NRx Pharma, Cardinal Health Ink Zyesami Distribution Pact

• NRx Pharmaceuticals Inc (NASDAQ: NRXP) has signed an agreement with Cardinal Health Inc (NYSE: CAH) to provide third-party logistics and distribution of Zyesami upon the potential FDA Emergency Use Authorization (EUA) approval.

• In May, NRx applied for EUA to the FDA for Zyesami (aviptadil) for critical COVID-19 patients with respiratory failure.

• Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for Zyesami.

• In July, NRx validated the first commercial formulation with better stability of Zyesami. NRx also said that it has "achieved a 30-to-50 fold increase" in the manufactured lot size of the drug.

• Also Read: Why NRx Pharma Stock Is Trading Higher In Mid Day Session Wednesday?

• Price Action: NRXP shares are up 5.19% at $13.58 during the market session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• NRx Pharma Stock Under Pressure On Equity Raise Of M

• Why NRx Pharma Stock Is Trading Higher In Mid Day Session Wednesday?

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.